QLife

On 28 January 2025, Qlife signed a Letter of Intent (LOI) with a top-20 global pharmaceutical company to explore potential commercial collaborations. Among the key criteria outlined in the LOI was Qlife's ability to test and integrate specific biomarkers into the Egoo Health platform. The company has now successfully verified these biomarkers, generating positive data. This confirmation demonstrates that the biomarkers covered in the LOI are compatible with the Egoo Health platform, reinforcing the feasibility of their integration.

"We look forward to presenting these data and expect that this will further advance discussions toward a partnership. As always, further validation of the biomarkers is required, and other parameters still need to be confirmed. However, it is very positive that the biomarkers have been fundamentally proven on the platform."- says Thomas Warthoe, CEO Qlife.